| Drug Name |
Latanoprost |
| Drug ID |
BADD_D01251 |
| Description |
Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment.[A184493] It has been found to be well-tolerated and its use does not normally result in systemic adverse effects like other drugs used to treat elevated intraocular pressure, such as [Timolol]. Another benefit latanoprost is that it can be administered once a day.[A184490] |
| Indications and Usage |
Latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with open-angle glaucoma or ocular hypertension.[L8357] Latanoprost may be combined in a product with [Netarsudil], a rho kinase inhibitor, for the same indications.[L8369] In addition to the above indications, the Canadian monograph for this drug also approves latanoprost for the treatment of elevated intraocular pressure as a result of angle-closure glaucoma that has been treated with peripheral iridotomy or laser iridoplasty.[L8366] |
| Marketing Status |
approved; investigational |
| ATC Code |
S01EE01 |
| DrugBank ID |
DB00654
|
| KEGG ID |
D00356
|
| MeSH ID |
D000077338
|
| PubChem ID |
5311221
|
| TTD Drug ID |
D0C6NM
|
| NDC Product Code |
65727-026; 82187-1002; 71205-154; 62991-3186; 65427-007; 82231-111; 50090-1920; 59762-0333; 54893-0010; 63190-0710; 65326-004; 61314-547; 65862-872; 0009-5172; 12079-0475; 42385-039; 51552-1385; 51927-4864; 68245-0002; 81997-001; 10695-048; 90027-006; 47335-317; 70069-421; 65035-128; 71684-0547; 73212-027; 55545-0462; 71052-041; 24208-463; 64980-516; 68071-4612; 40016-001; 61556-050; 0013-8303; 24002-0018; 73377-237 |
| UNII |
6Z5B6HVF6O
|
| Synonyms |
Latanoprost | PhXA34 | PHXA41 | Xalatan |
